- Home
- SGD vs ACXP Comparison
SGD vs ACXP Comparison
Compare SGD & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGD | ACXP |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 6.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SGD | ACXP |
|---|---|---|
| Price | $0.42 | $4.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $143.67 |
| AVG Volume (30 Days) | ★ 724.1K | 80.1K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,970,752.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2770.15 | N/A |
| 52 Week Low | $0.64 | $3.17 |
| 52 Week High | $3.03 | $25.00 |
Technical Indicators
Market Signals| Indicator | SGD | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 24.91 | 49.03 |
| Support Level | $0.74 | $3.17 |
| Resistance Level | $1.22 | $4.60 |
| Average True Range (ATR) | 0.12 | 0.41 |
| MACD | -0.04 | 0.07 |
| Stochastic Oscillator | 2.16 | 74.08 |
Price Performance
Historical ComparisonAbout SGD Safe and Green Development Corporation
Safe & Green Development Corp is a real estate development company that focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe and Green Holdings factories. The company's business model is flexible and it anticipates developing properties on its own and also through joint ventures in which it partners with third-party equity investors or other developers.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.